$AMED
AMEDISYS INC

2021 Q4 Form 10-Q Financial Statement

#000089626221000110 Filed on November 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $559.3M $553.5M $544.1M
YoY Change 1.56% 1.72% 10.01%
Cost Of Revenue $299.7M $310.3M $297.7M
YoY Change -2.3% 4.24% 3.11%
Gross Profit $259.7M $246.7M $246.4M
YoY Change 6.42% 0.12% 19.67%
Gross Profit Margin 46.42% 44.57% 45.29%
Selling, General & Admin $184.9M $178.9M $179.6M
YoY Change 5.27% -0.37% 16.1%
% of Gross Profit 71.19% 72.53% 72.89%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $9.138M $7.487M $8.300M
YoY Change 3.84% -9.8% 93.02%
% of Gross Profit 3.52% 3.03% 3.37%
Operating Expenses $194.0M $186.4M $187.9M
YoY Change 5.14% -0.79% 18.1%
Operating Profit $65.67M $56.80M $63.30M
YoY Change 10.37% -10.27% 35.26%
Interest Expense -$1.774M $2.730M $2.692M
YoY Change 121.75% 1.41% -28.75%
% of Operating Profit -2.7% 4.81% 4.25%
Other Income/Expense, Net $492.0K -$796.0K -$1.104M
YoY Change -18.0% -27.9% -57.54%
Pretax Income $46.88M $55.98M $62.21M
YoY Change -24.38% -10.02% 40.6%
Income Tax $12.87M $10.73M -$10.20M
% Of Pretax Income 27.46% 19.17% -16.4%
Net Earnings $34.05M $45.01M $71.98M
YoY Change -24.51% -37.48% 111.09%
Net Earnings / Revenue 6.09% 8.13% 13.23%
Basic Earnings Per Share $1.38 $2.20
Diluted Earnings Per Share $1.037M $1.37 $2.16
COMMON SHARES
Basic Shares Outstanding 32.60M shares 32.61M shares 32.66M shares
Diluted Shares Outstanding 32.90M shares 33.26M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.69M $124.5M $112.9M
YoY Change -47.81% 10.24% 442.79%
Cash & Equivalents $42.70M $124.5M $112.9M
Short-Term Investments
Other Short-Term Assets $25.60M $14.02M $30.11M
YoY Change 92.47% -53.43% 123.76%
Inventory
Prepaid Expenses $10.36M $16.08M $14.91M
Receivables $275.0M $274.6M $250.8M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $356.7M $432.9M $411.3M
YoY Change -1.46% 5.26% 37.3%
LONG-TERM ASSETS
Property, Plant & Equipment $18.44M $20.38M $24.10M
YoY Change -22.22% -15.45% -19.57%
Goodwill $1.196B $1.188B $931.5M
YoY Change 28.24% 27.54% 41.03%
Intangibles $111.2M $118.1M $84.14M
YoY Change 49.85% 40.34% 26.59%
Long-Term Investments $53.10M $48.30M
YoY Change
Other Assets $73.02M $68.11M $33.28M
YoY Change 119.95% 104.65% -38.67%
Total Long-Term Assets $1.500B $1.505B $1.191B
YoY Change 24.48% 26.29% 30.52%
TOTAL ASSETS
Total Short-Term Assets $356.7M $432.9M $411.3M
Total Long-Term Assets $1.500B $1.505B $1.191B
Total Assets $1.857B $1.938B $1.603B
YoY Change 18.49% 20.9% 32.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $38.22M $41.65M $39.04M
YoY Change -10.44% 6.69% 8.74%
Accrued Expenses $150.8M $154.3M $170.7M
YoY Change -9.24% -9.65% 34.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $13.00M $13.20M $10.70M
YoY Change 23.81% 23.36% 18.89%
Total Short-Term Liabilities $374.3M $454.3M $437.5M
YoY Change -17.98% 3.85% 39.04%
LONG-TERM LIABILITIES
Long-Term Debt $432.1M $434.8M $300.6M
YoY Change 111.3% 44.64% 29.79%
Other Long-Term Liabilities $4.979M $31.99M $44.39M
YoY Change -85.18% -27.93% 639.52%
Total Long-Term Liabilities $437.1M $466.8M $345.0M
YoY Change 83.57% 35.31% 45.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $374.3M $454.3M $437.5M
Total Long-Term Liabilities $437.1M $466.8M $345.0M
Total Liabilities $880.6M $988.8M $845.0M
YoY Change 16.42% 17.03% 38.77%
SHAREHOLDERS EQUITY
Retained Earnings $639.1M $605.0M $384.8M
YoY Change 48.62% 57.21% 75.94%
Common Stock $728.1M $720.9M $690.1M
YoY Change 4.27% 4.46% 8.7%
Preferred Stock
YoY Change
Treasury Stock (at cost) $435.9M $420.7M $318.8M
YoY Change 36.6% 31.96% 26.96%
Treasury Stock Shares 5.165M shares 5.069M shares 4.655M shares
Shareholders Equity $931.4M $905.3M $756.2M
YoY Change
Total Liabilities & Shareholders Equity $1.857B $1.938B $1.603B
YoY Change 18.49% 20.9% 32.2%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $34.05M $45.01M $71.98M
YoY Change -24.51% -37.48% 111.09%
Depreciation, Depletion And Amortization $9.138M $7.487M $8.300M
YoY Change 3.84% -9.8% 93.02%
Cash From Operating Activities $5.166M $61.77M $83.00M
YoY Change -92.17% -25.58% 74.74%
INVESTING ACTIVITIES
Capital Expenditures -$1.387M -$2.391M -$1.300M
YoY Change -39.7% 83.92% -63.89%
Acquisitions
YoY Change
Other Investing Activities -$10.28M -$262.2M $100.0K
YoY Change -1568.57% -262270.0% 0.0%
Cash From Investing Activities -$11.67M -$264.6M -$1.200M
YoY Change 629.19% 21946.75% -66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -75.94M 238.4M -146.7M
YoY Change -21.31% -262.48% 296.49%
NET CHANGE
Cash From Operating Activities 5.166M 61.77M 83.00M
Cash From Investing Activities -11.67M -264.6M -1.200M
Cash From Financing Activities -75.94M 238.4M -146.7M
Net Change In Cash -82.44M 35.56M -64.90M
YoY Change 156.82% -154.8% -1040.58%
FREE CASH FLOW
Cash From Operating Activities $5.166M $61.77M $83.00M
Capital Expenditures -$1.387M -$2.391M -$1.300M
Free Cash Flow $6.553M $64.16M $84.30M
YoY Change -90.41% -23.89% 64.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
AMEDISYS INC
dei Entity Central Index Key
EntityCentralIndexKey
0000896262
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83357000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124458000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
297668000 USD
dei Document Type
DocumentType
10-Q
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19955000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1464339000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
203756000 USD
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-24260
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3131700
dei Entity Address Address Line1
EntityAddressAddressLine1
3854 American Way
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A
dei Entity Address City Or Town
EntityAddressCityOrTown
Baton Rouge
dei Entity Address State Or Province
EntityAddressStateOrProvince
LA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
70816
dei City Area Code
CityAreaCode
225
dei Local Phone Number
LocalPhoneNumber
292-2031
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
AMED
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32602425 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124458000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81808000 USD
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
3750000 USD
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1549000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
274570000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
255145000 USD
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16080000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10217000 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
14024000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13265000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
432882000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
361984000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100407000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
95024000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20381000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23719000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100028000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
93440000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
1188054000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
932685000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
20309000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
22973000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
118084000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
74183000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
10111000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
47987000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
68105000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33200000 USD
CY2021Q3 us-gaap Assets
Assets
1937645000 USD
CY2020Q4 us-gaap Assets
Assets
1567198000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
41649000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
42674000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
155123000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
146929000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
154264000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
166192000 USD
CY2021Q3 amed Provider Relief Fund Advance
ProviderReliefFundAdvance
58535000 USD
CY2020Q4 amed Provider Relief Fund Advance
ProviderReliefFundAdvance
60000000 USD
CY2021Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
13225000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
10496000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
31553000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
30046000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
454349000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
456337000 USD
CY2021Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
434781000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
204511000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
67723000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61987000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31991000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33622000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
988844000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
756457000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1567198000 USD
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
38000 USD
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2020Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37659284 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37470212 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32590775 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32814278 shares
CY2021Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
38000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
720875000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1937645000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
698287000 USD
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
5068509 shares
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
4655934 shares
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
420665000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
319092000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
605016000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
429991000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
905264000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
809224000 USD
CY2021Q3 us-gaap Minority Interest
MinorityInterest
43537000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
1517000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
948801000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
810741000 USD
CY2021Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
553485000 USD
CY2020Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
544070000 USD
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1654795000 USD
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
7124000 USD
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1520814000 USD
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-4000 USD
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
4812000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
13300000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
27592000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
310294000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
297668000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
916188000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
878633000 USD
CY2021Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
119373000 USD
CY2020Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
123146000 USD
us-gaap Labor And Related Expense
LaborAndRelatedExpense
349533000 USD
us-gaap Labor And Related Expense
LaborAndRelatedExpense
330329000 USD
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
4397000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19758000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
17860000 USD
CY2021Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
55158000 USD
CY2020Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
49348000 USD
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
158995000 USD
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
142616000 USD
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7487000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8283000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21763000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19955000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
496709000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
485569000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1464339000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1391291000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
56772000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
63313000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
203756000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
157115000 USD
CY2021Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
0 USD
CY2020Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
31000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
49000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
258000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
2730000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
2692000 USD
us-gaap Interest Expense
InterestExpense
6734000 USD
us-gaap Interest Expense
InterestExpense
8675000 USD
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1444000 USD
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1435000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3932000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2399000 USD
CY2021Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
0 USD
CY2020Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
0 USD
us-gaap Gain Loss On Investments
GainLossOnInvestments
31092000 USD
us-gaap Gain Loss On Investments
GainLossOnInvestments
-2980000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
490000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
122000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1253000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
662000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-796000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1104000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29592000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8336000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
55976000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
62209000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
233348000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
148779000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10731000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10202000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
57192000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
875000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9175000 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
45245000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
72411000 USD
us-gaap Profit Loss
ProfitLoss
176156000 USD
us-gaap Profit Loss
ProfitLoss
139604000 USD
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
239000 USD
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
430000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1131000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1147000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
45006000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
71981000 USD
us-gaap Net Income Loss
NetIncomeLoss
175025000 USD
us-gaap Net Income Loss
NetIncomeLoss
138457000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.38
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.26
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3022000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32607000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32662000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32658000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32469000 shares
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.37
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.16
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32899000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33260000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33021000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33267000 shares
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
875887000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1061000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1083000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4397000 USD
CY2021Q3 amed Surrendered Shares
SurrenderedShares
9750000 USD
CY2021Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
10805000 USD
CY2021Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
459000 USD
CY2021Q3 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
42142000 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
45245000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
948801000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
722259000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
914000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3123000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7124000 USD
CY2020Q3 amed Surrendered Shares
SurrenderedShares
47788000 USD
CY2020Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
300000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
72411000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
757743000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
810741000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1706000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17860000 USD
amed Surrendered Shares
SurrenderedShares
16694000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
84879000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1253000 USD
us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
42142000 USD
us-gaap Profit Loss
ProfitLoss
176156000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
948801000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
641513000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2600000 USD
amed Stock Issued During Period Value Four Zero One K Employer Match
StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
3057000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6070000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19758000 USD
amed Surrendered Shares
SurrenderedShares
54172000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
672000 USD
amed Equity Impact Of Write Off Of Other Comprehensive Income
EquityImpactOfWriteOffOfOtherComprehensiveIncome
15000 USD
us-gaap Profit Loss
ProfitLoss
139604000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
757743000 USD
us-gaap Profit Loss
ProfitLoss
176156000 USD
us-gaap Profit Loss
ProfitLoss
139604000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21763000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19955000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
17860000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19758000 USD
amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
30181000 USD
amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
29149000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
64000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
77000 USD
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
31092000 USD
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-2980000 USD
amed Write Off Of Other Comprehensive Income
WriteOffOfOtherComprehensiveIncome
0 USD
amed Write Off Of Other Comprehensive Income
WriteOffOfOtherComprehensiveIncome
15000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
25594000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
34729000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2762000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3932000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2399000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
669000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
653000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
4268000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
3919000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17638000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6486000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6219000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
28217000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
938000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
91000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1192000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1627000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-9363000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1785000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
38481000 USD
amed Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-27372000 USD
amed Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-25576000 USD
amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2304000 USD
amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2775000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
183727000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
223040000 USD
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
126000 USD
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
94000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
140000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
80000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5187000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2995000 USD
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
147000 USD
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
0 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 USD
us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
0 USD
us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
17876000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
264872000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
299723000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-269940000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-285543000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1706000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6070000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3022000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2600000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
16694000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
54172000 USD
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
1253000 USD
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
672000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
290312000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
500700000 USD
CY2021Q3 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
38 state
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
551700000 USD
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
357000000 USD
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
432000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5893000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
7360000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2792000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
84879000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
amed Funds Received From Provider Relief Fund Advance
FundsReceivedFromProviderReliefFundAdvance
-1465000 USD
amed Funds Received From Provider Relief Fund Advance
FundsReceivedFromProviderReliefFundAdvance
60000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
131064000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
81466000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
44851000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
18963000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83357000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
96490000 USD
CY2020Q3 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128208000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115453000 USD
us-gaap Interest Paid Net
InterestPaidNet
3479000 USD
us-gaap Interest Paid Net
InterestPaidNet
4902000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
25482000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
30290000 USD
amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
29676000 USD
amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
28351000 USD
amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
1509000 USD
amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
1483000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
34881000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
29876000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
814000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
822000 USD
amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
1183000 USD
amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
767000 USD
CY2021Q3 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div>
CY2021Q3 amed Minimum Percent Ownership For Controlling Interest Percent
MinimumPercentOwnershipForControllingInterestPercent
0.50
CY2021Q3 amed Maximum Percent Ownership For Equity Method Percent
MaximumPercentOwnershipForEquityMethodPercent
0.50
CY2021Q3 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
48300000 USD
CY2020Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
14200000 USD
CY2021Q3 amed Number Of Consolidated Entities Classified As Variable Interest Entities
NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities
7 numberOfJointVentures
amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
CY2021Q3 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
CY2020Q3 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Episode Payment Rate Duration
NetServiceRevenueEpisodePaymentRateDuration
P60D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2020 amed Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care
RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
0.20
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Percentage Of Total Reimbursement Of Outlier Payment
PercentageOfTotalReimbursementOfOutlierPayment
0.10
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
CY2021Q3 amed Cash Balance Associated With Provider Relief Fund
CashBalanceAssociatedWithProviderReliefFund
58500000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81800000 USD
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
3800000 USD
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1500000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128200000 USD
amed Percentage Of Patient Receivables Outstanding
PercentageOfPatientReceivablesOutstanding
0.10
CY2021Q3 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.65
CY2020Q4 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.64
amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
CY2020 amed Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care
RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
0.20
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2020Q1 amed Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements
FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
30000000000 USD
CY2021Q3 amed Debt Instrument Carrying Amount Excluding Finance Leases
DebtInstrumentCarryingAmountExcludingFinanceLeases
450800000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32607000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32662000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32658000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32469000 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
113000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
336000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
135000 shares
CY2021Q3 amed Total Leverage Ratio
TotalLeverageRatio
1.2
CY2021Q3 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
179000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
506000 shares
CY2020Q3 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
262000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
228000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
292000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32899000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33260000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33021000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33267000 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
141000 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
82000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31000 shares
CY2020Q1 amed Funding For Healthcare Providers Including Hospitals
FundingForHealthcareProvidersIncludingHospitals
175000000000 USD
CY2020Q1 amed Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements
FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
30000000000 USD
CY2020Q2 amed Funding Received From Cares Act
FundingReceivedFromCARESAct
100000000 USD
amed Health Insurance Retention Limit
HealthInsuranceRetentionLimit
1300000 USD
CY2021Q3 amed Consolidated Interest Coverage Ratio
ConsolidatedInterestCoverageRatio
27.5
CY2021Q3 amed Provider Relief Fund Advance
ProviderReliefFundAdvance
59000000 USD
CY2020Q4 amed Provider Relief Fund Advance
ProviderReliefFundAdvance
60000000 USD
amed Cares Act Provider Relief Funds Utilized
CARESActProviderReliefFundsUtilized
46600000 USD
CY2021Q3 amed Cares Act Interest To Be Repaid To Government
CARESActInterestToBeRepaidToGovernment
200000 USD
CY2021Q3 amed Estimated Cares Act Provider Relief Fund Amounts To Be Repaid
EstimatedCARESActProviderReliefFundAmountsToBeRepaid
58300000 USD
amed Cares Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures
CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures
1300000 USD
CY2021Q3 amed Estimated Cares Act Provider Relief Fund Amounts To Be Repaid By Unconsolidated Joint Ventures
EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures
600000 USD
CY2021Q3 amed Total Cares Act Provider Relief Funds Received
TotalCARESActProviderReliefFundsReceived
106800000 USD
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
452800000 USD
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
217700000 USD
CY2021Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
4800000 USD
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2700000 USD
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
448000000.0 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
215000000.0 USD
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
13200000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
10500000 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
434800000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
204500000 USD
amed Workers Compensation Insurance Retention Limit
WorkersCompensationInsuranceRetentionLimit
1000000 USD
amed Professional Liability Insurance Retention Limit
ProfessionalLiabilityInsuranceRetentionLimit
300000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 Segments
CY2021Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
553500000 USD
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
310300000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
178900000 USD
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7500000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
496700000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
56800000 USD
CY2020Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
544100000 USD
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
4800000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
179700000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8300000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
485600000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
63300000 USD
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1654800000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
13300000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
916200000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
526400000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21800000 USD
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1520800000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
27600000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
878600000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
492800000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1391300000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
157100000 USD

Files In Submission

Name View Source Status
0000896262-21-000110-index-headers.html Edgar Link pending
0000896262-21-000110-index.html Edgar Link pending
0000896262-21-000110.txt Edgar Link pending
0000896262-21-000110-xbrl.zip Edgar Link pending
amed-20210930.htm Edgar Link pending
amed-20210930.xsd Edgar Link pending
amed-20210930_cal.xml Edgar Link unprocessable
amed-20210930_def.xml Edgar Link unprocessable
amed-20210930_g1.jpg Edgar Link pending
amed-20210930_htm.xml Edgar Link completed
amed-20210930_lab.xml Edgar Link unprocessable
amed-20210930_pre.xml Edgar Link unprocessable
amed-20213009xex32.htm Edgar Link pending
amed-20213009xexx311.htm Edgar Link pending
amed-20213009xexx312.htm Edgar Link pending
amed-20213009xexx321.htm Edgar Link pending
amed-20213009xexx322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending